Prognostic value of neutrophil to lymphocyte ratio and lymphocyte counts before durvalumab consolidation after radio-chemotherapy in locally advanced non-small cell lung cancer

Arnaud Colomb,Benoit Allignet,Mehdi Lamkhioued,Aurelie Swalduz,Lionel Falchero,Aurélie Kienlen,Michaël Duruisseaux,Coralie Moncharmont
DOI: https://doi.org/10.1186/s13014-024-02553-z
IF: 4.309
2024-11-10
Radiation Oncology
Abstract:Durvalumab, an anti-PD-L1 immune checkpoint inhibitor, after radio-chemotherapy (RCT) has changed the management of locally advanced non-small cell lung cancer (LA NSCLC). A series of retrospective studies have investigated different cut-off of lymphocyte count (LyC) and neutrophil-to-lymphocyte ratio (NLR) to predict survival in LA NSCLC. None of these studies has validated their threshold in an independent group of patients. We wanted to assess the OS prognostic value of NLR and LyC in patients with LA NSCLC treated by RCT and durvalumab, with threshold determination and their validation in an external cohort.
oncology,radiology, nuclear medicine & medical imaging
What problem does this paper attempt to address?